Bios



Payam Nahid, MD, MPH

Dr. Payam Nahid, the Haile T. Debas Distinguished Professor of Global Health, is the Executive Director of the UCSF Institute for Global Health Sciences. With over two decades of experience in global health, he specializes in clinical trials and translational research on TB and HIV/TB co-infection. Dr. Nahid has led international programs funded by NIH, CDC, USAID, and BMGF to develop new TB diagnostics and treatments. In 2009, he co-founded the Vietnam National TB Programme-UCSF Research Collaboration Unit to promote equitable international research activities. As the Senior Research Advisor for the USAID-funded Supporting, Mobilizing and Accelerating Research for Tuberculosis Elimination (SMART4TB), Dr. Nahid directs the consortium's research strategies. Dr. Nahid serves as the Director of the UCSF Center for Tuberculosis and co-leads the NIAID-funded UCSF-UC Berkeley TB Research Advancement Center (UC TRAC), which trains early-stage TB investigators. Dr. Nahid has led WHO Task Forces and international practice guidelines. He is an appointed member of the WHO Strategic and Technical Advisory Group on TB (STAG TB).



Lisa Chen, MD

Dr. Lisa Chen is a Professor of Medicine in the division of Pulmonary and Critical Care Medicine at the University of California San Francisco. She heads the Curry International TB Center at UCSF, which has served as a CDC Center of Excellence for TB training, education, and consultation for the past 30 years. She is the immediate Past-president for the North American Region International Union Against Tuberculosis and Lung Disease (NAR IUATLD) and serves on the Coordinating Board for STOP-TB USA and the federal DHHS Advisory Council for the Elimination of TB. Dr. Chen's international contributions for over 15+ years have been as a technical program advisor and education specialist for the development and strengthening of national programmatic management of drug-resistant tuberculosis (PMDT), has served as a contributor/reviewer for both domestic and international guideline on DR-TB, and has been the co-editor for the last two editions of the CITC Drug-Resistant TB Survival Guide.



Brian Graham, MD

Dr. Graham is pulmonary division chief at SFGH and hold the John Murray Distinguished Professorship in Pulmonary Medicine



Philip Hopewell, MD

Dr. Phil Hopewell is professor of medicine, emeritus, at the University of California, San Francisco based at Zuckerberg San Francisco General Hospital where he served as Chief of the Division of Pulmonary and Critical Care Medicine and as Associate Dean. He is the co-founder of the Curry International Tuberculosis Center at UCSF. His academic career has focused on clinical and epidemiological studies of TB and HIV-associated pulmonary conditions in both low-and high-burden settings. Dr Hopewell is a previous President of the American Thoracic Society and in 2004 received the Society's Trudeau Medal that recognizes lifelong major contributions to the prevention, diagnosis, and treatment of lung disease. He was also awarded the Louis Mark Medal from the American College of Chest Physicians, and the Union Medal from the International Union Against Tuberculosis and Lung Diseases. Dr Hopewell has worked closely with the World Health Organization, United States Agency for International Development, and other organizations to establish and disseminate best practices on TB diagnosis, treatment, and control. He developed the concept and chaired the committee that produced the first International Standards for TB Care and led the effort to implement the Standards globally. In 2009 the Japan Anti-Tuberculosis Association awarded him The Princess Chichibu Global Memorial TB Award in recognition of outstanding contributions to global TB control.



Jonathan Budzik, MD, PhD

Dr. Jon Budzik graduated from Dartmouth College with a BA in Molecular Biology & Biochemistry and Oxford University with a MSc in Human Anatomy & Genetics. In the MD-PhD program at the University of Chicago, he at UC San Francisco, he obtained post-doctoral training in M. tuberculosis pathogenesis at UC Berkeley. He joined the faculty as an Assistant Professor at UC San Francisco in 2021. His lab is focused on understanding innate immune responses to M. tuberculosis infection.







Elizabeth Fair, PhD, MPH

Dr. Elizabeth Fair is an infectious disease epidemiologist with a primary faculty appointment in the Department of Medicine, Division of Pulmonary and Critical Care Medicine. Dr. Fair's research interests include intensified case finding for TB in high burden settings, global health, and operational research. She serves as a co-Director of the UCSF Center for Tuberculosis, co-Director of the TB Research and Mentoring Program (TB RAMP) and the TRAC Global Fellows Program, and co-Director of the Development Core of the UC TRAC. Dr. Fair also serves as Director of Education for the UCSF Institute for Global Health Sciences (IGHS) where she teaches, mentors, and serves as Director of the Global Health PhD program.



Christopher Rae, PhD

Dr. Christopher Rae is a postdoctoral researcher and TB RAMP scholar in Jeffery Cox's Lab at UC Berkeley. He is a structural biologist studying how the cell envelope of *M. tuberculosis* is assembled and how this critical barrier contributes to virulence and antibiotic resistance



Anne Allué Guardia, PhD

Dr. Allué Guardia is a Staff Scientist II at Texas Biomedical Research Institute studying the adaptation of Mycobacterium tuberculosis (*M.tb*) to the lung environment. Dr. Allué Guardia received her Ph.D. in Environmental Microbiology and Biotechnology from the University of Barcelona, Spain, and has worked with different bacterial pathogens during her postdoctoral studies. Her scientific background is in microbiology, molecular biology, and microbial genomics and transcriptomics, with experience in Next Generation Sequencing (NGS) technologies. She joined Texas Biomed in 2018. Dr. Allué Guardia current research focuses on understanding how *M.tb* adapts to our lungs during the first stages of infection and how these early events are critical drivers of infection outcomes. Specifically, she studies how the alveolar lining fluid modifies the cell envelope and metabolism of *M.tb*. Her ultimate goal is to identify key early host and *M.tb* factors that can serve as novel targets for TB treatment and diagnostics. Dr. Allué Guardia has also been involved in COVID-19 research projects, including the validation of small animal models and in vitro 3D systems for studying SARS-CoV-2 infection.



Lisa Marie Crammer, MD, MPH

Dr. Lisa Marie Cranmer, MD, MPH, is a physician scientist at the Emory University School of Medicine and Rollins School of Public Health. She has formal training in pediatric infectious disease, clinical research, and epidemiology with over 10 years' experience conducting global TB and HIV clinical and translational studies. She has particular interest and expertise in TB vaccine trials, TB/HIV coinfection in pregnant women and children, and translational immunology studies. She is currently the Protocol Chair for an IMPAACT/HVTN TB vaccine trial in pre-adolescents, and PI of an NIH-funded study to evaluate the effect of maternal antibodies on the risk of infant Mtb infection



Benjamin Gern, MD

Dr. Ben Gern is a Principal Investigator at Seattle Children's Research Institute, and an Assistant Professor of Pediatrics at the University of Washington. His lab focuses of the mechanistic dissection of spatially resolved host-pathogen interactions during Mycobacterium tuberculosis infection. Through the use of relevant mouse models, human tissues, advanced immunologic tools, and cutting-edge quantitative imaging the Gern Lab investigates what factors limit immunity within the pulmonary lesion, with the ultimate goal of informing the design of improved treatments and vaccines.



Manish Gupta, PhD

Dr. Manish Gupta is a postdoctoral associate working with Prof. William R. Bishai at the Center for Tuberculosis Research in the School of Medicine at Johns Hopkins University. As an early-stage investigator, Dr. Gupta aims to distinguish the diverse impacts of genetics and sex hormones on innate and adaptive immune responses in males and females, contributing to sex differences in susceptibility to TB infections. He is interested in predicting sex-linked biomarkers and the development of precision medicine interventions for TB, including host-directed therapies.

World TB Day Symposium



Bios



Alexander Mohapatra, MD, PhD

Dr. Alex Mohapatra received his PhD in Immunology and his MD from the University of California, San Francisco (UCSF). He then completed a residency in Internal Medicine and a fellowship in Pulmonary & Critical Care Medicine at UCSF. He is now an Assistant Professor in the Department of Medicine at UCSF. Dr. Mohapatra studies the myeloid cells in the lung that engulf Mycobacterium tuberculosis to develop novel therapies that can improve their ability to kill the pathogen. He also studies the T cell response in tuberculosis to develop new tuberculosis vaccines.



Matthew Murrill, MD, PhD

Dr. Matthew Murrill is an Assistant Professor of Hospital Medicine and an infectious disease epidemiologist. His overarching research goal is to improve tuberculosis (TB) prevention by leveraging epidemiologic and implementation science methods. His primary research interests are to: (1) understand gaps in TB preventive care by combining disparate data sources; (2) design and evaluate interventions to improve these gaps, (3) address fundamental questions of TB epidemiology that limit our ability to target TB prevention to individuals who would most benefit.



Kayvan Zainabadi, PhD

Dr. Kayvan Zainabadi is an Assistant Professor of Molecular Microbiology in the Center for Global Health at Weill Cornell Medicine. Dr. Zainabadi received his PhD in molecular biology from MIT and completed his postdoctoral training at NIAID. He has spent 6 of the last 12 years performing molecular diagnostics research in India, Myanmar and most recently Haiti where he has developed new methods to detect HPV, malaria and TB in low-resource settings. His current research focuses on: 1) TB persistence, including understanding the molecular regulation of differentially detectable/culturable *Mtb* persisters that likely play a role in poor treatment outcomes; and 2) Developing more sensitive and specific RNA-based diagnostics to detect paucibacillary TB and better predict treatment outcomes.



Caitlin Moe, MS, PhD

Dr. Caitlin Moe is a global health epidemiologist whose work focuses on screening strategies and diagnostics for TB. She holds an MS in Global Health Sciences from UCSF and a PhD in Epidemiology from the University of Washington.



Devan Jaganath, MD, PhD

Dr. Devan Jaganath is an Assistant Professor of Pediatrics in the Division of Pediatric Infectious Diseases at UCSF. He leads the Maternal and Childhood TB initiative at the UCSF Center for Tuberculosis, which seeks to advance the care, education, and research for TB in pregnancy and childhood. In research, he is interested in developing and accessing new diagnostics and digital tools to improve TB care. He is also a core faculty member of the UCSF/UC Berkeley Joint Program in Computational Precision Health and is the data science lead for NIH-funded biomarker discovery projects to identify biosignatures for TB diagnosis in children. In digital health, he oversees several international efforts to advance artificial intelligence (AI)-based tools for TB, including automated algorithms that utilize cough sounds or chest radiography to predict TB disease in adults and children. Locally, he is interested in the role of the electronic health record (EHR) to improve screening and treatment of TB infection and has overseen the implementation of new EHR TB tools for children at UCSF Health.



Priya Shete, MD, PhD

Dr. Priya Shete is an Associate Professor in Residence of Medicine and Epidemiology based in the Division of Pulmonary and Critical Care Medicine at UCSF. Her research portfolio leverages methods in implementation science, social epidemiology, modelling, and health policy to identify critical gaps in the coverage and uptake of quality TB care as well as to support national TB programs and departments of public health with the design and implementation of interventions that curb these barriers. She is the principal investigator of several implementation science studies to improve TB program implementation both domestically and globally, aimed at improving person-centered care and reducing health system inefficiencies. Prior to joining the faculty at UCSF, Dr. Shete worked with the Global TB Programme of the World Health Organization and served as a public health advisor at USAID. Dr. Shete directs the UCSF Implementation Science Training Program, the California Collaborative for Public Health Research, and the Clinical and Population Health Science Core for the Center for TB. She continues to care for patients with pulmonary disease at Zuckerberg San Francisco General Hospital.



Janice Louie, MD, MPH

Dr. Janice Louie is Medical Director of the San Francisco Department of Public Health Tuberculosis Prevention and Control Program, and Associate Clinical Professor at the University of California San Francisco Department of Medicine. Her primary focus is to ensure continued excellence in the clinical management of tuberculosis, provide mentorship to trainees, share knowledge and training with community providers, and advancing clinical practices in tuberculosis with a focus on serving marginalized populations.



Fatoumatta Darboe, PhD

Dr. Fatoumatta Darboe is an Assistant professional researcher in the Suliman lab at UCSF. She completed her PhD, clinical sciences and immunology at the University of Cape Town in the lab of Professor Thomas Scriba. During this time she worked on projects defining correlates of risk and protection from TB disease and comorbidities, especially in people living with HIV. Her pioneering work in developing blood-based biomarkers, such as the Darboe11 signature, has significantly advanced the understanding of TB pathogenesis and treatment response. She previously served as a postdoc at the Medical Council Unit The Gambia, where she led projects aimed at understanding the effects of TB disease on long-term lung health and continued her pursuit of biomarker development. In the Suliman lab, she is continuing her work on defining correlates of risk and protection from TB disease and comorbidities such as HIV. Her work is instrumental in informing vaccine design and host-directed therapy in immunocompromised persons at risk of developing TB disease.



Sophie Huddart, PhD

Dr. Sophie Huddart is a tuberculosis epidemiologist and postdoctoral scholar at UCSF. She is interested in TB quality of care, especially how it influences the long-term outcomes of people with TB.